Galapagos delivers validated oncology targets to Janssen
In January 2008, BioFocus entered into a fee-for-service target discovery collaboration with Janssen, under which BioFocus developed assays in cancer cells, and discovered and validated novel targets. In January 2010, BioFocus received a target acceptance payment from Janssen for identifying and validating drug targets. BioFocus has now confirmed the activity of a panel of targets across several key pathways in oncology, per contractually defined criteria. BioFocus may receive success-based payments should certain downstream criteria be reached by Janssen.
"We continue to see strong demand for our target discovery capabilities and this collaboration is an example of how we deliver novelty to pharmaceutical pipelines," said Onno van de Stolpe, Chief Executive Officer of Galapagos.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.